Telix Pharmaceuticals Limited (NASDAQ:TLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT
Company Participants
Christian Behrenbruch – Co-Founder, MD, Group CEO & Executive Director
Conference Call Participants
David Bailey – Morgan Stanley, Research Division
Presentation
David Bailey
Equity Analyst
Okay. Good afternoon, everyone. We’re here with the second last session of the day. My name is David Bailey. I’m part of the Australian health care team at Morgan Stanley.
Before we get going, I just have to read this out quickly. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Question-and-Answer Session
David Bailey
Morgan Stanley, Research Division
So welcome, Dr. Chris Behrenbruch, CEO of Telix. Maybe just for those who are a little bit less familiar with your company, just a bit of an overview. A bit of background would be great as a starting question.
Christian Behrenbruch
Co-Founder, MD, Group CEO & Executive Director
Yes. Thanks, and thanks for the opportunity. So we’re globally active, I guess, you call it a pure-play radiopharmaceutical company. We are a commercial stage company, a little bit unusual in the sense that we have a deep pipeline of products, and I’ll talk a little bit about that more in a second, but we are commercializing our products as well in the major markets we serve. We’re clinically and commercially active in 26 countries.
We have sort of 3 pillars of value creation in the company. We have a portfolio of products that target what we think are exciting targets in cancers and rare diseases, where we target that we go after. We develop both an imaging agent and a therapeutic because we think that, that precision medicine strategy is extremely important. And in
